Can-Fite BioPharma Ltd. (CANF) Press Releases https://ir.canfite.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/canfite/files/theme/images/logo-sm.png Can-Fite BioPharma Ltd. Logo Equisolve Investor Relations Suite <![CDATA[Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026]]> https://ir.canfite.com/news-events/press-releases/detail/1109/can-fites-partner-vetbiolix-completes-enrollment-in Mon, 30 Mar 26 07:20:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1109/can-fites-partner-vetbiolix-completes-enrollment-in <![CDATA[Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient]]> https://ir.canfite.com/news-events/press-releases/detail/1108/can-fite-reports-2025-financial-results-and-ongoing Thu, 26 Mar 26 09:27:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1108/can-fite-reports-2025-financial-results-and-ongoing <![CDATA[Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance]]> https://ir.canfite.com/news-events/press-releases/detail/1107/can-fite-expands-namodenoson-anti-obesity-franchise-with Tue, 17 Mar 26 07:47:00 -0400 https://ir.canfite.com/news-events/press-releases/detail/1107/can-fite-expands-namodenoson-anti-obesity-franchise-with <![CDATA[Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds]]> https://ir.canfite.com/news-events/press-releases/detail/1106/can-fite-announces-exercise-of-warrants-for-approximately Wed, 04 Mar 26 10:25:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1106/can-fite-announces-exercise-of-warrants-for-approximately <![CDATA[Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study]]> https://ir.canfite.com/news-events/press-releases/detail/1105/can-fites-namodenoson-successfully-meets-primary Wed, 04 Mar 26 07:00:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1105/can-fites-namodenoson-successfully-meets-primary <![CDATA[Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson]]> https://ir.canfite.com/news-events/press-releases/detail/1104/can-fite-announces-scientific-breakthrough-publication Tue, 17 Feb 26 07:00:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1104/can-fite-announces-scientific-breakthrough-publication <![CDATA[Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy]]> https://ir.canfite.com/news-events/press-releases/detail/1103/can-fite-receives-canadian-patent-allowance-for Mon, 09 Feb 26 07:00:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1103/can-fite-receives-canadian-patent-allowance-for <![CDATA[Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson]]> https://ir.canfite.com/news-events/press-releases/detail/1102/can-fite-patient-with-decompensated-liver-cirrhosis Thu, 05 Feb 26 07:00:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1102/can-fite-patient-with-decompensated-liver-cirrhosis <![CDATA[Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson]]> https://ir.canfite.com/news-events/press-releases/detail/1101/can-fite-completes-patient-enrollment-in-phase-2a Tue, 20 Jan 26 07:00:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1101/can-fite-completes-patient-enrollment-in-phase-2a <![CDATA[Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction]]> https://ir.canfite.com/news-events/press-releases/detail/1100/can-fite-granted-brazilian-patent-for-treatment-of-sexual Fri, 26 Dec 25 07:00:00 -0500 https://ir.canfite.com/news-events/press-releases/detail/1100/can-fite-granted-brazilian-patent-for-treatment-of-sexual